Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER): Study Design and Progress Update (P2.269)

Conclusion: The GRIPPER study may provide clinically relevant outcomes data for CIDP patients receiving IVIg and explore the relationship between IVIg dosing, interval, and treatment-related fluctuations in routine clinical practice. Patient recorded GS is feasible and practical. Serum IgG levels and clinical response to IVIg may develop better evidence based dosing strategies.Disclosure: Dr. Allen has nothing to disclose. Dr. Pasnoor has nothing to disclose. Dr. Burns has received personal compensation in an editorial capacity for Neurology. Dr. Ajroud-Driss has nothing to disclose. Dr. Ney has received personal compensation for activities with Surgical Neuromonitoring, PLLC and Surgical Neuromonitoring Associates. Dr. Cook has nothing to disclose. Dr. Kissel has received personal compensation for activities with Alexion Pharmaceuticals, Cytokinetics, and ISIS Pharmaceuticals as an advisor. Dr. Gorson has received personal compensation for activities with CSL Behring. Dr. Lewis has received personal compensation for activities with CSL Behring, Pharnext, Novartis, and Axelacare. Dr. Berger has nothing to disclose. Dr. Riley has nothing to disclose. Dr. Schaefer has nothing to disclose. Dr. Timothy has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Allen, J., Pasnoor, M., Burns, T., Ajroud-Driss, S., Ney, J., Cook, A., Kissel, J., Gorson, K., Lewis, R., Berger, M., Riley, P., Schaefer, D., Timothy, W. Tags: Treatments of Peripheral Neuropathies and Cramps Source Type: research